Filing Overview
Evaxion Biotech A/S filed a Form 6-K for March 2022 on March 7, 2022. The filing reports completion of recruitment for the Phase 1/2a clinical trial of EVX-02 immunotherapy in patients with adjuvant melanoma.
Business Context
EVX-02 is an immunotherapy candidate being evaluated in the adjuvant melanoma setting. The filing states that recruitment for the Phase 1/2a trial has been finalized.
Financial Information
The filing does not provide financial statements, revenue, profit or loss, cash flow, margins, debt, liquidity, cash balance, or other financial metrics.
Material Developments
- Recruitment for the Phase 1/2a EVX-02 clinical trial in adjuvant melanoma patients was completed.
- The filing includes the related March 7, 2022 press release as Exhibit 99.1.
- The report is incorporated by reference into the company’s Form S-8 registration statement, File No. 333-255064, to the extent not superseded by subsequent filings.
Outlook, Risks and Unusual Items
The filing does not provide clinical results, efficacy or safety findings, regulatory milestones, financial guidance, commercialization timing, or detailed risk factors. Completion of recruitment does not establish the trial’s clinical or regulatory outcome.
Investor Verification Points
- Verify the number of enrolled patients and the trial’s stated primary and secondary endpoints.
- Review subsequent disclosures for interim or final EVX-02 safety and efficacy data.
- Confirm the expected timing of clinical readouts and any regulatory interactions.
- Assess the company’s cash resources and financing needs in its latest Form 20-F or other financial filings, as this 6-K provides no liquidity information.